Puretech presents preclinical proof-of-concept data for lyt-300 (oral allopregnanolone) as potential treatment for neurological and neuropsychological conditions

Boston--(business wire)--puretech presented preclinical proof-of-concept data at the acnp annual meeting that support the clinical advancement of lyt-300.

PRTC Ratings Summary

PRTC Quant Ranking